Showing results (401-410 of 432) with videos related to
Sort By:
Pageof 44
Leukemia|August 5, 2024
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance studyElena Crisà, Elvira Mora, Ulrich Germing, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Marie Robin, Matteo Bersanelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO TrialUwe Platzbecker, Lionel Adès, Pau Montesinos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2025
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic SyndromesMatteo Zampini, Elena Riva, Luca Lanino, et al.Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.Haematologica|May 28, 2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative studySabine Kayser, Richard F Schlenk, Delphine Lebon, et al.Cancer Cell|May 20, 2014
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivoPetter S Woll, Una Kjällquist, Onima Chowdhury, et al.The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.Leukemia|April 30, 2026
How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified?Maria Julia Montoro, Pamela Acha, Claudia Haferlach, et al.Pageof 44